Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
We have just published a MARA Rating for an obesity treatment that has not yet completed Phase 3 trials. The Phase 2 data answered one question clearly: can this drug
Summary Servier agreed on June 1 to acquire sevasemten from Edgewise Therapeutics for up to $2.7 billion. The drug targets two forms of muscular dystrophy: Duchenne (DMD) and Becker (BMD).
We recently completed a MARA Rating for a treatment for a kidney disease that can progress to kidney failure over time. The phase 3 trial answered one question clearly: does
We have just published a MARA Rating for a preparative treatment used before stem cell transplants in blood cancers. The clinical question: does this improve survival compared to the established
Summary CVS Caremark will add Eli Lilly’s oral obesity medicine Foundayo to its formularies on June 1, 2026. Zepbound returns as a preferred option from October 1. Both changes reverse
A MARA Rating we completed for an Alzheimer’s treatment arrived with one of the highest public profiles in recent memory. The phase 3 trial showed meaningful slowing of cognitive decline.
AstraZeneca received FDA approval on May 18, 2026, for Baxfendy, the first aldosterone synthase inhibitor cleared for adults with uncontrolled hypertension. Click here to go to our independent assessment. https://mararating.com/report/baxdrostat-for-treatment-resistant-hypertension-as-of-april-2026/The
We have just published a MARA Rating for a maintenance treatment in lung cancer. The trial answered one question clearly: does this treatment extend survival? It does. Patients lived longer
In HTA-driven environments, stability in reimbursement positioning often reflects persistence of structural constraints rather than absence of progress. Following a structured surveillance reassessment, the MARA Rating for baxdrostat in treatment-resistant
Brensocatib, poised for its first FDA decision in non-cystic fibrosis bronchiectasis, shows clear clinical benefits but faces major U.S. market access challenges. We examine Phase 3 ASPEN trial results, safety